Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia

Ibrutinib has dramatically altered the therapeutic landscape of chronic lymphocytic leukemia (CLL) with remarkable responses in relapsed or refractory as well as in previously untreated CLL harboring TP53 aberrations.[1][1],[2][2] Despite durable responses in the majority of cases, approximately 20